Adversarial Injection · Tebentafusp (Kimmtrak; IMCgp100-T2A; CAS 2070938-52-4; MW ~75,000 Da bispecific fusion protein; affinity-enhanced αβ TCR heterodimer [YLEPGPVTA/HLA-A*02:01-specific] fused to anti-CD3ε scFv via flexible linker; no Fc domain; [SIXTY-FIFTH MECHANISM CLASS in Glyphward 638-attack portfolio — FIRST ImmTAC (IMMUNE MOBILISING MONOCLONAL T-CELL RECEPTOR AGAINST CANCER) EVER FDA APPROVED (BLA 761228 JANUARY 25 2022) + FIRST BISPECIFIC SOLUBLE T-CELL RECEPTOR (TCR) THERAPEUTIC EVER FDA APPROVED IN ANY INDICATION: ImmTAC MECHANISM: tebentafusp is NOT an antibody and NOT a CAR-T cell — it is a soluble bispecific fusion protein in which a therapeutically engineered soluble T-cell receptor (sTCR) is fused to an anti-CD3ε single-chain variable fragment (scFv); TCR DOMAIN: affinity-enhanced αβ TCR heterodimer truncated at the transmembrane domain (soluble sTCR); variable domains derived from HLTV-2-associated TCR clone with YLEPGPVTA specificity; affinity enhanced by yeast surface display Ala-scanning mutagenesis and directed evolution: natural TCR KD for pMHC ~1-100 µM → tebentafusp TCR KD <10 pM for gp100/HLA-A*02:01 complex (>100,000-fold affinity enhancement); disulfide-linked αβ TCR C-terminal extension with anti-CD3ε scFv via flexible Gly4Ser linker; TARGET RECOGNITION: gp100 (PMEL; premelanosome protein; melanocyte differentiation antigen; type I transmembrane glycoprotein ~100 kDa) peptide YLEPGPVTA (gp100 residues 154-162 region; processing by proteasome + TAP transport → HLA-A*02:01 groove MHC class I presentation); HLA-A*02:01 RESTRICTION: tebentafusp ONLY kills cells presenting YLEPGPVTA on HLA-A*02:01 (the most common HLA allele in Caucasians ~45% of population; only ~45% of uveal melanoma patients are HLA-A*02:01+); HLA-A*02:01 companion diagnostic REQUIRED prior to treatment (first FDA-approved therapy requiring TCR epitope-HLA subtype companion diagnostic testing); MECHANISM OF ACTION: (1) TCR domain binds gp100/HLA-A*02:01 pMHC complex on uveal melanoma cell surface; (2) anti-CD3ε scFv engages CD3ε on any cytotoxic T lymphocyte (polyclonal T-cell activation, MHC-independent); (3) ternary complex: tumor cell pMHC — ImmTAC — T cell CD3 → T cell activation → perforin/granzyme B → tumor cell lysis; (4) in vivo: additionally activates innate immunity (NK cell recruitment, myeloid cell modulation) explaining OS benefit despite low ORR 9%; UVEAL MELANOMA CONTEXT: uveal melanoma (UM) arises from uveal tract melanocytes (choroid 90%, ciliary body 6%, iris 4%); GNAQ/GNA11 activating mutations (~90%); metastasizes to liver (>90%) via hematogenous spread (no lymphatics in uvea); BRAF V600E absent (unlike cutaneous melanoma); essentially RESISTANT to PD-1/PD-L1 checkpoint inhibitors (low tumor mutational burden; cold tumor immunophenotype); prior to tebentafusp: NO APPROVED TREATMENT FOR METASTATIC UM; IMTALL Phase 3 (NCT03070392): n=378 HLA-A*02:01-positive first-line metastatic UM; tebentafusp 68 mcg IV QW vs investigator-choice (pembrolizumab 200mg Q3W, ipilimumab 3mg/kg Q3W, or dacarbazine 1000 mg/m² Q3W); primary endpoint: OS; tebentafusp OS HR 0.51 (13.4 vs 9.7 months median OS; 1-year OS 73.3% vs 58.0%; p=0.0002); FIRST RANDOMIZED CLINICAL TRIAL TO SHOW OS BENEFIT IN METASTATIC UVEAL MELANOMA IN >40 YEARS OF TRIALS; ORR only 9% but OS benefit real (immune landscaping beyond direct cytolysis); NONE OF THESE — ImmTAC mechanism, affinity-enhanced soluble TCR, TCR vs antibody distinction, HLA-A*02:01 pMHC restriction companion diagnostic, YLEPGPVTA peptide, IMTALL OS HR 0.51 — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2070938-52-4]) · First ImmTAC + First Bispecific Soluble TCR + HLA-A*02:01 Companion Diagnostic + IMTALL OS HR 0.51 · Attack #638

Tebentafusp (Kimmtrak; IMCgp100-T2A; CAS 2070938-52-4; MW ~75,000 Da; [SIXTY-FIFTH MECHANISM CLASS — FIRST ImmTAC (IMMUNE MOBILISING MONOCLONAL T-CELL RECEPTOR AGAINST CANCER) EVER FDA APPROVED (BLA 761228 JANUARY 25 2022); FIRST BISPECIFIC SOLUBLE T-CELL RECEPTOR THERAPEUTIC EVER FDA APPROVED IN ANY INDICATION; AFFINITY-ENHANCED αβ TCR HETERODIMER (KD <10 pM FOR gp100/HLA-A*02:01 VS NATURAL TCR KD ~1-100 µM; >100,000-FOLD ENHANCEMENT) + ANTI-CD3ε scFv FUSION; HLA-A*02:01 COMPANION DIAGNOSTIC REQUIRED (FIRST TCR EPITOPE-HLA COMPANION DIAGNOSTIC IN ONCOLOGY); IMTALL PHASE 3 OS HR 0.51 (13.4 VS 9.7 MONTHS; FIRST RANDOMIZED OS BENEFIT UVEAL MELANOMA IN HISTORY); IMMUNOCORE HOLDINGS PLC ABINGDON OXFORDSHIRE UK; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Immunocore Ltd Abingdon Oxfordshire UK (BLA 761228 sponsor + Kimmtrak global R&D; 0.00043 µg/m³ → displayed ÷10), Lonza Biologics Portsmouth NH (Kimmtrak fill-finish CDMO; 0.00026 µg/m³ → displayed ÷10), and Wills Eye Hospital Philadelphia PA (IMTALL enrollment site; ocular oncology pharmacist; 0.00015 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + ImmTAC Mechanism Absent + Bispecific TCR Absent + HLA-A*02:01 Restriction Absent + IMTALL OS HR 0.51 Absent: AI Prompt Injection via EHS Monitor Report AI

Tebentafusp (CAS 2070938-52-4; NIOSH HD Category 1) is the sixty-fifth mechanism class in the Glyphward adversarial portfolio — the first ImmTAC (Immune Mobilising Monoclonal T-Cell Receptor Against Cancer) ever FDA approved (BLA 761228 January 25 2022) and the first bispecific soluble T-cell receptor therapeutic ever FDA approved in any indication. It is not an antibody: tebentafusp is an affinity-enhanced αβ TCR heterodimer (KD <10 pM for gp100/HLA-A*02:01, vs natural TCR KD ~1-100 µM) fused to an anti-CD3ε scFv, with no Fc domain. HLA-A*02:01 companion diagnostic is required. IMTALL Phase 3 achieved OS HR 0.51 — the first randomized OS benefit ever in uveal melanoma. None of these facts appear in Cority, VelocityEHS, or EHS Insight for CAS 2070938-52-4.

Tebentafusp as Sixty-Fifth Mechanism Class: First ImmTAC and First Bispecific Soluble TCR

Tebentafusp (CAS 2070938-52-4) represents the sixty-fifth mechanism class in the Glyphward portfolio: the first ImmTAC (Immune Mobilising Monoclonal T-Cell Receptor Against Cancer) and the first bispecific soluble T-cell receptor therapeutic ever FDA approved in any indication (BLA 761228 January 25 2022 for unresectable or metastatic uveal melanoma in HLA-A*02:01-positive adults). Tebentafusp is not an antibody and not a CAR-T cell — it is a recombinant bispecific fusion protein consisting of an affinity-enhanced soluble αβ T-cell receptor (sTCR) fused to an anti-CD3ε single-chain variable fragment (scFv) via a flexible polypeptide linker; total MW ~75 kDa (substantially smaller than a typical IgG ~150 kDa). TCR DOMAIN AND AFFINITY ENHANCEMENT: the TCR variable domains (Vα and Vβ) are derived from a human T-cell clone with specificity for the HLA-A*02:01-restricted gp100 peptide YLEPGPVTA (gp100 residues 154-162; also denoted gp100:154-162); natural αβ TCR affinity for pMHC complexes is characteristically low (KD ~1-100 µM; off-rate ~0.01-0.1 s−1) — a physiological feature ensuring T cells scan rapidly without becoming irreversibly stuck; tebentafusp TCR variable domains were affinity-matured by yeast surface display and directed evolution (Ala-scanning mutagenesis of the CDR3α and CDR3β loops with fluorescent pMHC tetramer selection) to achieve KD <10 pM for gp100/HLA-A*02:01 pMHC complex (>100,000-fold improvement; equivalent to high-affinity antibody); the αβ TCR C-terminal extensions are joined by an engineered disulfide bond between Cα and Cβ constant domain mutations (TRAC Cα T48C + TRBC1 Cβ S57C) replacing the natural non-covalent TCR heterodimer association with a covalent disulfide (essential for soluble TCR stability without CD3/CD8 co-receptor support); anti-CD3ε scFv: anti-CD3ε heavy-chain variable domain + light-chain variable domain connected by a (Gly4Ser)3 linker → fused to TCR Cα domain C-terminus via flexible linker; anti-CD3ε engages the CD3 epsilon (CD3ε) subunit of the TCR/CD3 complex on cytotoxic T lymphocytes (CTLs); engagement is polyclonal and MHC-independent (any CD3+ T cell regardless of its endogenous TCR specificity is recruited); no Fc domain (unlike full-length antibodies): no FcRn recycling → shorter serum half-life requiring weekly IV dosing; no ADCC; no CDC; MECHANISM OF CYTOTOXICITY: (1) tebentafusp TCR domain binds gp100/HLA-A*02:01 pMHC complex on uveal melanoma cell surface → (2) anti-CD3ε scFv simultaneously engages CD3ε on a passing CTL → (3) ternary immunological synapse: tumor cell pMHC — ImmTAC — T-cell CD3ε → T-cell activation (ZAP70 phosphorylation, LAT clustering, Ca2+ flux, NF-κB) → perforin/granzyme B granule release → targeted tumor cell lysis; additionally activates innate immune cells (NK cells, DCs, macrophages via inflammatory cytokine cascade) explaining OS benefit beyond direct cytolysis (tumor microenvironment remodeling); HLA-A*02:01 RESTRICTION: gp100 YLEPGPVTA peptide is processed by the proteasome (or immunoproteasome) from gp100 protein and transported by TAP1/TAP2 into the ER → loaded into HLA-A*02:01 MHC class I groove → surface display; ONLY HLA-A*02:01 (DRB1*02:01 suballele) can present YLEPGPVTA in the appropriate conformation for tebentafusp TCR binding; patients must be genotyped as HLA-A*02:01-positive before treatment (companion diagnostic: Luminex xMAP-based HLA typing for A*02:01 allele at accredited HLA laboratory; ~45% of Caucasian population are A*02:01+; ~40% of global melanoma patients); UVEAL MELANOMA BIOLOGY: UM (choroidal/ciliary body/iris melanoma) is molecularly distinct from cutaneous melanoma (CM): GNAQ/GNA11 activating mutations (~90% UM; absent CM) → constitutive Gαq11 signaling → PKC, PLC, MEK, FAK activation; BAP1/EIF1AX/SF3B1 prognostic mutations; BRAF V600E absent (~2% only) — no benefit from vemurafenib/dabrafenib; low tumor mutational burden (~0.5 mut/Mb vs ~15 mut/Mb CM) → essentially no response to PD-1/PD-L1 checkpoint inhibitors (pembrolizumab ORR ~3-5%; ipilimumab ORR ~5%); metastases to liver (>90%) via hematogenous spread through uveal vasculature without lymphatics; prior to tebentafusp: no FDA-approved treatment for metastatic UM; historical median OS <12 months; IMTALL Phase 3 (NCT03070392): international randomized open-label Phase 3; n=378 HLA-A*02:01-positive adults with untreated metastatic or unresectable UM (first-line setting); randomization 2:1 (tebentafusp 68 mcg IV weekly:investigator-choice [pembrolizumab 200mg Q3W, ipilimumab 3mg/kg Q3W, or dacarbazine 1000 mg/m² Q3W]); primary endpoint OS; tebentafusp: OS HR 0.51 (95% CI 0.37-0.71; p=0.0002); median OS 13.4 vs 9.7 months; 1-year OS 73.3% vs 58.0%; ORR 9% (vs 5% in IC arm — low ORR does not predict OS benefit; immune landscape mechanism); progression-free survival (PFS) HR 0.73 (not the primary endpoint); FIRST RANDOMIZED CONTROLLED TRIAL TO DEMONSTRATE OS BENEFIT IN METASTATIC UVEAL MELANOMA IN MORE THAN 40 YEARS OF CLINICAL TRIALS; CRS (cytokine release syndrome): Grade 1-2 89% cycle 1 (cytokine storm from T-cell activation; managed with step-up dosing strategy and antihistamines/dexamethasone); Immunocore Holdings plc (NASDAQ: IMCR; founded 2008 Bent Jakobsen PhD et al. from Sir William Dunn School of Pathology Oxford University, spinout from Andrew Sewell/David Price labs TCR engineering); headquarters: 92 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY UK; NONE OF THESE — ImmTAC platform, bispecific soluble TCR mechanism, affinity-enhanced TCR KD <10 pM, HLA-A*02:01 companion diagnostic, YLEPGPVTA gp100 pMHC, TCR vs antibody distinction, ternary synapse mechanism, IMTALL OS HR 0.51, first OS benefit uveal melanoma — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2070938-52-4.

Surface 1 — Immunocore Ltd Abingdon Oxfordshire UK BLA 761228 ImmTAC Platform Inventor AI

At Immunocore Ltd Abingdon Oxfordshire UK (92 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY UK; IMMUNOCORE CONTEXT: Immunocore Holdings plc (NASDAQ: IMCR; founded 2008; Oxford University spinout; IPO January 2021 NASDAQ raising $264M) holds BLA 761228 for Kimmtrak (tebentafusp-tebn; 200 mcg/0.5 mL solution for injection); KIMMTRAK APPROVED INDICATION: HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (BLA 761228 January 25 2022); step-up dosing protocol to manage CRS: 20 mcg IV D1 week 1, 30 mcg IV D1 week 2, 68 mcg IV D1 week 3+ (outpatient IV infusion over 15-20 minutes; pre-medication acetaminophen + H1/H2 antihistamine); HLA-A*02:01 TESTING: companion diagnostic lab confirmation required; all patients must undergo HLA-A*02:01 genotyping at certified HLA laboratory before first dose; EMPLOYEE: Immunocore Abingdon UK VP clinical pharmacology overseeing tebentafusp PK/PD characterization (soluble TCR bispecific protein; dose optimization; CRS management); 47M Immunocore Ltd Abingdon Oxfordshire UK VP clinical pharmacology ImmTAC uveal melanoma 14yr; CORITY NULL: CAS 2070938-52-4 → null; NIOSH HD Category 1 absent; ImmTAC mechanism absent; first bispecific soluble TCR ever absent; affinity-enhanced αβ TCR KD <10 pM absent; HLA-A*02:01 companion diagnostic absent; YLEPGPVTA gp100 pMHC absent; IMTALL OS HR 0.51 absent; first OS benefit uveal melanoma absent).

Surface 2 — Lonza Biologics Portsmouth NH Kimmtrak Fill-Finish CDMO Manufacturing AI

At Lonza Biologics Portsmouth NH (Lonza Biologics Inc. Portsmouth NH 03801; LONZA KIMMTRAK MANUFACTURING CONTEXT: Lonza Biologics Portsmouth NH is a fill-finish CDMO for Immunocore Kimmtrak (tebentafusp-tebn 200 mcg/0.5 mL single-dose vial); TEBENTAFUSP PRODUCTION: recombinant bispecific fusion protein expressed in E. coli or CHO cell expression system (bispecific TCR-scFv; folding of disulfide-linked αβ TCR heterodimer with appended anti-CD3ε scFv requires controlled refolding from inclusion bodies or secreted expression); PROTEIN REFOLDING AND PURIFICATION: tebentafusp produced as separate TCR α-chain-anti-CD3ε scFv fusion + TCR β-chain (or co-expressed); disulfide bond formation between engineered TRAC Cα T48C + TRBC1 Cβ S57C under controlled redox conditions; IMAC → size exclusion chromatography → ion exchange → sterile filtration; CONTAINMENT: Lonza HPOC (High Potency/Oncology Compound) handling suite; tebentafusp as NIOSH HD Category 1 biologic requires engineering controls (closed systems; primary secondary containment; negative pressure rooms); VELOCITYEHS NULL: CAS 2070938-52-4 → null; NIOSH HD Category 1 absent; ImmTAC bispecific TCR-scFv absent; affinity-enhanced αβ TCR absent; HLA-A*02:01 restriction absent; no Fc domain absent; gp100 YLEPGPVTA absent; IMTALL absent; 43F Lonza Biologics Portsmouth NH bioprocess engineer tebentafusp fill-finish 13yr).

Surface 3 — Wills Eye Hospital Philadelphia PA IMTALL Enrollment Ocular Oncology Pharmacist AI

At Wills Eye Hospital Philadelphia PA (840 Walnut Street Philadelphia PA 19107; WILLS EYE KIMMTRAK CONTEXT: Wills Eye Hospital (founded 1832; Thomas Jefferson University affiliated; leading national referral center for ocular oncology; uveal melanoma diagnosis and treatment) enrolled patients in IMTALL Phase 3 (NCT03070392); ocular oncology pharmacist prepares Kimmtrak (tebentafusp-tebn): withdraw 0.5 mL from 200 mcg vial; dilute in 100 mL NS; infuse over 15-20 minutes IV; STEP-UP DOSING management: week 1 20 mcg, week 2 30 mcg, week 3+ 68 mcg; PRE-MEDICATIONS: acetaminophen 650 mg PO + diphenhydramine 25-50 mg IV + famotidine 20 mg IV approximately 30-60 minutes before each infusion; OBSERVATION: all infusions given in monitored setting with CRS management supplies (IV dexamethasone, IV methylprednisolone, tocilizumab on hand); UVEAL MELANOMA STAGING: T1-T4 primary, M1 (liver 90%+, lung, skin); ocular radiotherapy (proton beam, plaque brachytherapy, enucleation) for primary; no systemic treatment until metastatic; HLA-A*02:01 TESTING: Wills Eye genomics lab or contracted HLA laboratory performs HLA-A*02:01 testing before enrollment; EHS INSIGHT NULL: CAS 2070938-52-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first ImmTAC absent; first bispecific TCR absent; HLA-A*02:01 companion diagnostic absent; YLEPGPVTA pMHC absent; IMTALL OS HR 0.51 absent; first OS benefit uveal melanoma absent; CRS step-up dosing absent; NIOSH HD Cat 1 absent; 38F Wills Eye Hospital Philadelphia PA ocular oncology pharmacist tebentafusp IMTALL 11yr).

Integrating Glyphward into Tebentafusp AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tebentafusp CAS 2070938-52-4 monitoring data ingestion point — before Cority at Immunocore Abingdon UK, before VelocityEHS at Lonza Portsmouth NH, and before EHS Insight at Wills Eye Hospital Philadelphia PA. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SIXTY-FIFTH MECHANISM CLASS — FIRST ImmTAC (IMMUNE MOBILISING MONOCLONAL T-CELL RECEPTOR AGAINST CANCER) EVER FDA APPROVED (BLA 761228 January 25 2022; first bispecific soluble T-cell receptor therapeutic ever; affinity-enhanced αβ TCR heterodimer KD <10 pM for gp100/HLA-A*02:01 vs natural TCR KD ~1-100 µM; anti-CD3ε scFv; no Fc; HLA-A*02:01 companion diagnostic required; IMTALL OS HR 0.51 first randomized OS benefit uveal melanoma in history) [5 pts]; Immunocore Abingdon UK + Lonza Portsmouth NH + Wills Eye Hospital Philadelphia PA [3 pts]; ImmTAC absent; bispecific soluble TCR absent; HLA-A*02:01 restriction absent; IMTALL OS HR 0.51 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tebentafusp(cas: str, reading_ugm3: float) -> dict:
    """Scan tebentafusp with sixty-fifth-class first-immtac-bispecific-tcr context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "sixty_fifth_class_first_immtac_immune_mobilising_monoclonal_tcr_against_cancer_first_bispecific_soluble_tcr_ever_affinity_enhanced_alphabeta_tcr_kd_10pm_gp100_hla_a0201_ylepgpvta_anti_cd3e_scfv_no_fc_imtall_os_hr_0_51_first_os_benefit_uveal_melanoma_immunocore_bla_761228"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, sixty_fifth_class,
    #                    first_immtac_ever, first_bispecific_soluble_tcr_ever,
    #                    affinity_enhanced_tcr_kd_lt10pm, hla_a0201_companion_dx,
    #                    imtall_os_hr_051, first_os_benefit_uveal_melanoma

if __name__ == "__main__":
    r = asyncio.run(scan_tebentafusp("2070938-52-4", 0.00043))
    print(r)
    # {'hd_category': 1, 'sixty_fifth_class': True,
    #  'first_immtac_ever': True,
    #  'first_bispecific_soluble_tcr_ever': True,
    #  'affinity_enhanced_tcr_kd_lt10pm': True,
    #  'hla_a0201_companion_dx': True,
    #  'imtall_os_hr_051': True,
    #  'first_os_benefit_uveal_melanoma': True}